Pay in 4 interest-free payments of $5.30 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
The effect of GLP-1R agonists liraglutide and exendin-4 was examined in vitro on LOVO, CA-77, MCF-7, MDA-MB-231, KPL-1, MB-468, 4TI, BT483, ZR751, LNCap, PC3, ALVA-41, DU145, LNCap, PANC-1, MiaPaCa-2, PANC, CT26, SKOV3, OVCAR3, OVCAR4, A2780, and ES-2 cell lines that are expressed in several cancers including colorectal, pancreatic, thyroid, breast, prostate, ovarian, and colon (Table 1)
This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal (eg, St
doi: 10.3389/fnins.2025.1671955 Received 24 July 2025 Revised 10 December 2025 Accepted 16 December 2025 Published 13 January 2026 Volume 19 - 2025 Edited by Fangchen Gong, Shanghai Jiao Tong University, China Reviewed by Al-Shaimaa Faissal Ahmed, Minia University, Egypt John Sieh Dumbuya, Affiliated Hospital of Guangdong Medical University, China Updates Copyright 2026 Li, Wang, Ma, Peng, Wang, Wang, Li and Wang
Robust human RCT data is absent
Without specialized delivery systems that can better protect the delicate chain of molecules, Amiji says, many of the peptides marketed online are unlikely to ever reach those intended targets
Doctors want to check how well it works for many types of patients and get the right facts for FDA approval
